Rigel Pharmaceuticals Inc expected to post a loss of 8 cents a share - Earnings Preview

Rigel Pharmaceuticals

29/07/2023 24:43

* Rigel Pharmaceuticals Inc  RIGL.OQ   RIGL.O  is expected
to show
a fall in quarterly revenue when it reports  results on August
1. 
    * The South San Francisco California-based  company is
expected to
report  a 13.8% decrease in revenue to $25.704 million from
$29.82 million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Rigel
Pharmaceuticals Inc
is for a loss of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $2​, above​ its last closing price
of $1.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.09       -0.10      -0.08     Beat    17.9
 Dec. 31 2023  -0.11       -0.11      0.01      Beat    108.9
 Sep. 30 2022  -0.13       -0.13      -0.11     Beat    18.2​
 Jun. 30 2022  -0.13       -0.12      -0.08     Beat    34.8
 ​​Mar.        -0.14       -0.14      -0.16     Missed  -16.5
 31 2022                                                
 Dec. 31 2021  -0.13       -0.13      -0.13     Met     -1.8​
 Sep. 30 2021  -0.09       -0.10      -0.12     Missed  -20.4
 Jun. 30 2021  -0.11       -0.11      -0.08     Beat    30
 This summary was machine generated July 28 at 23:43 GMT.  All
figures in US dollars  unless otherwise stated